» Articles » PMID: 11779739

A Role for Cysteinyl Leukotrienes in Airway Remodeling in a Mouse Asthma Model

Overview
Specialty Critical Care
Date 2002 Jan 10
PMID 11779739
Citations 112
Authors
Affiliations
Soon will be listed here.
Abstract

Airway inflammation and remodeling in chronic asthma are characterized by airway eosinophilia, hyperplasia of goblet cells and smooth muscle, and subepithelial fibrosis. We examined the role of leukotrienes in a mouse model of allergen-induced chronic lung inflammation and fibrosis. BALB/c mice, after intraperitoneal ovalbumin (OVA) sensitization on Days 0 and 14, received intranasal OVA periodically Days 14-75. The OVA-treated mice developed an extensive eosinophil and mononuclear cell inflammatory response, goblet cell hyperplasia, and mucus occlusion of the airways. A striking feature of this inflammatory response was the widespread deposition of collagen beneath the airway epithelial cell layer and also in the lung interstitium in the sites of leukocytic infiltration that was not observed in the saline-treated controls. The cysteinyl leukotriene(1) (CysLT(1)) receptor antagonist montelukast significantly reduced the airway eosinophil infiltration, mucus plugging, smooth muscle hyperplasia, and subepithelial fibrosis in the OVA-sensitized/challenged mice. The presence of Charcot-Leyden-like crystals in airway macrophages and the increased interleukin (IL)-4 and IL-13 mRNA expression in lung tissue and protein in BAL fluid seen in OVA-treated mice were also inhibited by CysLT(1) receptor blockade. These data suggest an important role for cysteinyl leukotrienes in the pathogenesis of chronic allergic airway inflammation with fibrosis.

Citing Articles

Deciphering the Interplay between the Epithelial Barrier, Immune Cells, and Metabolic Mediators in Allergic Disease.

Kan L, Li P, Hon S, Lai A, Li A, Wong K Int J Mol Sci. 2024; 25(13).

PMID: 39000023 PMC: 11241838. DOI: 10.3390/ijms25136913.


Impact of obesity on airway remodeling in asthma: pathophysiological insights and clinical implications.

Listyoko A, Okazaki R, Harada T, Inui G, Yamasaki A Front Allergy. 2024; 5:1365801.

PMID: 38562155 PMC: 10982419. DOI: 10.3389/falgy.2024.1365801.


A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms.

Kordjazy N, Amini S Ther Adv Respir Dis. 2024; 18:17534666241232284.

PMID: 38504551 PMC: 10953006. DOI: 10.1177/17534666241232284.


Ym1 protein crystals promote type 2 immunity.

Heyndrickx I, Deswarte K, Verstraete K, Verschueren K, Smole U, Aegerter H Elife. 2024; 12.

PMID: 38194250 PMC: 10945506. DOI: 10.7554/eLife.90676.


Study on the mechanism of PM2.5 affecting Th1/Th2 immune imbalance through the notch signaling pathway in asthmatic mice.

Wu J, He Z, Bao H, Zeng X, Liu X Toxicol Res (Camb). 2023; 12(4):675-684.

PMID: 37663808 PMC: 10470343. DOI: 10.1093/toxres/tfad044.